Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer

Part of paid clinical trials in Buffalo, New York.

Sponsor
Roswell Park Cancer Institute
Study ID
NCT00083148
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy, such as irinotecan and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may help capecitabine kill more tumor cells by making tumor cells more sensitive to the drug. PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan and capecitabine in treating women with advanced breast cancer.

Key Dates

Start date
Nov 30, 2002
Status verified
Mar 2011
Primary completion
Mar 31, 2005
Completion
Sep 30, 2006

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Roswell Park Cancer InstituteBuffaloNew York14263-0001-

Find similar trials in Buffalo, NY

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Roswell Park Cancer Institute· Buffalo, NY

Related Studies